All In Biotech

Drug Trial Radar · NCT03409614

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 789 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

789

Actual

Start

Mar 6, 2018

Primary completion

Feb 27, 2025

Study completion Feb 27, 2025

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Jan 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are: Part 1: To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with advanced squamous or nonsquamous non-small cell lung cancer (NSCLC) with tumors expressing PD-L1 in \<50% of tumor cells. Part 2: To compare the OS of cemiplimab/chemo-f with placebo/chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC irrespective of PD-L1 expression. The key secondary objectives are: Part 1: To compare the progression-free survival (PFS) and objective response rate (ORR) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC and tumors expressing PD-L1 in \<50% of tumor cells. Part 2: To compare the PFS and ORR of cemiplimab/chemo-f versus placebo/chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC irrespective of PD-L1 expression.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • REGN2810Drug

    REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2

  • REGN2810/chemo/ipiDrug

    REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1

  • ChemotherapyOther

    Platinum-based doublet chemotherapy Part 1

  • PlaceboDrug

    Matching placebo Part 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Overall Survival (OS)Time frame: Up to a maximum of 82.2 months
  2. Part 2: OSTime frame: Up to a maximum of 68.4 months

Locations

133 sites in 18 countries. Site status is shown where the registry gives one.

  • Regeneron Research Site

    Rancho Mirage, California

  • Regeneron Research Site

    Riverside, California

  • Regeneron Research Site

    Whittier, California

  • Regeneron Research Site

    Orange City, Florida

  • Regeneron Research Site

    St. Petersburg, Florida

  • Regeneron Research Site

    Wichita, Kansas

  • Regeneron Research Site

    Bethesda, Maryland

  • Regeneron Research Site

    Farmington, New Mexico

  • Regeneron Research Site

    Gettysburg, Pennsylvania

  • Regeneron Research Site

    Vienna, Austria

  • Regeneron Research Site

    Baoding, China

  • Regeneron research Site

    Beijing, China

  • Regeneron Research Site

    Changsha, China

  • Regeneron Research Site

    Guangzhou, China

  • Regeneron Research Site

    Hangzhou, China

  • Regeneron Research Site

    Hangzhou, China

  • Regeneron Research Site

    Hangzhou, China

  • Regeneron Research Site

    Hangzhou, China

  • Regeneron Research Site

    Jinan, China

  • Regeneron Research Site

    Linyi, China

  • Regeneron Research Site

    Nanjing, China

  • Regeneron Research Site

    Shanghai, China

  • Regeneron Research Site

    Shanghai, China

  • Regeneron Research Site

    Shenyang, China

  • Regeneron Research Site

    Xiangyang, China

  • Regeneron Research Site

    Zhengzhou, China

  • Regeneron Research Site

    Zhengzhou, China

  • Regeneron Research Site

    Bayonne, France

  • Regeneron Research Site

    Créteil, France

  • Regeneron Research Site

    Le Mans, France

  • Regeneron Research Site

    Lille, France

  • Regeneron Research Site

    Lyon, France

  • Regeneron Research Site

    Mont-de-Marsan, France

  • Regeneron Research Site

    Saint-Herblain, France

  • Regeneron Research Site

    Saint-Mandé, France

  • Regeneron Research Site

    Strasbourg, France

  • Regeneron Research Site

    Batumi, Georgia

  • Regeneron Research Site

    Tbilisi, Georgia

  • Regeneron Research Site

    Tbilisi, Georgia

  • Regeneron Research Site #1

    Tbilisi, Georgia

Showing 40 of 133 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.